132681An innovative PROstate cancer Screening Test based on the MCM5 ELISA Test (iPROSTMET)ClosedFeasibility StudiesInnovate UKEvery year 47,000 men are diagnosed with prostate cancer in the UK. Currently, diagnosis requires an invasive biopsy to be taken. This is painful for the patient, burdomesome to the NHS and carries the risk of infection requiring further treatment. Arquer have a simple test, optimised for bladder cancer, capable of detecting cancerous cells in urine. As prostate tumours shed cancerous cells into urine and semen, Arquer intend to adapt the test for use as a screening and diagnostic tool for prostate cancer. In order to successfully adapt the test from bladder to prostate cancer, Arquer need to execute studies to fully understand the pathways for prostate cancer diagnosis, where the Arquer test would fit in to the clinical pathway and identify any potential issues which may affect utility or attractiveness of the test. Arquer will then address these issues so that the test can be easily adopted by the NHS. Work will be carried out to ensure that the optimal performance parameters for the test are identified and implemented, allowing the design of a full clinical trial to be carried out following these studies. The final product will be a test which can accurately diagnose prostate cancer without the need for biopsy, benefiting patients and clinicians alike, whilst simultaneously providing large cost savings to the NHS.